About
Optune Lua® concurrent with PD-1/PD-L1 inhibitor or docetaxel is FDA-approved for adult patients with metastatic non–small cell lung cancer (mNSCLC) who have progressed on or after a platinum- based regimen.
Technologies
Cloudflare DNSMobile FriendlyVisual Website OptimizerVimeoGoogle Tag Manager
Keywords
medical equipment manufacturingoncology deviceclinical trial dataelectric field therapymedical devicesttfieldssystemic immune responsedocetaxelmitotic disruptionmedical equipment and supplies manufacturingdisrupt cancer cell divisionb2bquality of lifeadverse eventspd-1/pd-l1 inhibitorspatient adherencetransducer arraysoverall survival benefitimmunogenic cell deathmetastatic nsclccombination therapytumor treating fieldsdevice safety profileelectric fieldselectrical therapy in oncologywearable devicedevice portabilityfda-approved cancer therapyoncologysystemic toxicity
Company Information
- Employees0
